INDV

Indivior Pharmaceuticals, Inc. (INDV) | Rumor.io

Indivior Pharmaceuticals

INDV

Attention (50-day avg)0%

Attention rank (50-day avg)#2,054

Bullish sentiment (50-day avg)100%

Price to earnings ratio12.8

Market capitalization4.4B

Earnings per share2.79

Dividend yield (TTM)—

Revenue (annual)1.2B

Net income (annual)210M

Social

What share of all stock conversation is about INDV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to create a diversified CNS biopharmaceutical leader with significant scale, with a combined annual revenue of $2.2 billion.
The merger will give Supernus shareholders 1.54 Indivior shares for every share they own, and Indivior will provide a $1 billion special cash dividend to its shareholders before the deal closes.
The combined company will have 11 approved drugs in its portfolio and is expected to generate $125 million in annual cost savings.

Generated by AI

Sentiment

Of the messages about INDV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	96.08% +10.18
Bearish	—	0%	0% 0	3.92% -10.18

Nov 3

Indivior PLC has reported Q3 results that beat expectations and raised full-year guidance, leading to a re-pricing of the stock higher on both the top-line beat and the forward.
The company's earnings and guidance have driven a significant increase in the stock price, with Indivior shares up 5.2% due to the positive news.
Indivior's Q3 results have been met with enthusiasm from buyers, with a microscopic float and a high volume of 1.08M, indicating a strong demand for the stock.

Generated by AI

Topics

Of the messages about INDV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	41.17%
Technical Analysis	—	—	0%	46.62%
Earnings	—	—	0%	1.3%
Analysts	—	—	0%	2.73%
Controversies	—	—	0%	5.45%
Macro	—	—	0%	2.73%

Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive tax-free, all-stock merger of equals agreement, with Supernus stockholders receiving 1.54 Indivior shares per share, representing a value of $61.62 per Supernus share.
The combined company will have a pro forma net revenue of $2.2B, pro forma adjusted EBITDA of $888M, and 11 commercial products across CNS biopharmaceuticals, with a $1B special cash dividend before the deal closes.
Indivior reported Q2 2026 total net revenue of $343M, a 14% year-over-year increase, with SUBLOCADE revenue reaching a record $253M, and the company raising its FY26 guidance for revenue to $1.295B-$1.365B.

Generated by AI

Community

Of the messages about INDV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	6.45%	45.71%
Newcomers	—	100%	93.55%	54.29%

Aug 3

The merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals is expected to close in Q4 2026, with Supernus shareholders receiving 1.54 Indivior shares for every share they own, and Indivior shareholders receiving a $1 billion special cash dividend.
The combined company is expected to generate $125 million in annual cost synergies and have a combined revenue of $2.2 billion.
The merger is seen as a move to create a diversified CNS biopharmaceutical leader with greater growth flexibility, and the combined company's market capitalization is estimated to be around $4.9 billion.

Generated by AI

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”). The return of the rights follows Indivior’s ra

5d agoYahoo Finance Australia

Indivior (INDV) Receives a Rating Update from a Top Analyst

Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.

11d agoThe Globe and Mail

Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger

13d agoYahoo Finance

Indivior declares $8.13 special dividend contingent on merger

13d agoInvesting.com

Indivior Pharmaceuticals to end supply agreement with Reckitt Benckiser in January

14d agoInvesting.com

Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?

Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

27d agoYahoo Finance

Also Discussed

Investors talking about INDV also mention

#	Name	Attention
1	F/m 2-Year Investment Grade Corporate Bond ETFZTWO	0%0
2	PGIM Nasdaq-100 Buffer 12 ETF - JanuaryPQJA	0%0
3	RAPT - RAPT Therapeutics, Inc.	——
4	authID Inc.AUID	0%0
5	GPGI IncCMPO	0%0
6	Belite Bio, Inc. ADRBLTE	0%new
7	Atour Lifestyle Holdings Limited Sponsored ADRATAT	0%new
8	Nuvectis Pharma, Inc.NVCT	0%0
9	Agape Atp CorpATPC	0%0
10	Moolec Science SAMLEC	0%new

Indivior Pharmaceuticals, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on medicines for opioid use disorder and related substance use disorders. The company develops, manufactures, and markets buprenorphine-based prescription treatments designed to support recovery and long-term disease management in clinical settings. Its product portfolio includes branded therapies such as SUBLOCADE, SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX, which are used in addiction medicine and office-based treatment programs. Indivior serves patients, healthcare professionals, and treatment providers across the United States and other international markets, with a business centered on evidence-based care for chronic addiction conditions. The company also supports broader understanding of addiction medicine through clinical research, medical education, and treatment access initiatives. Headquartered in North Chesterfield, Virginia, Indivior plays a specialized role in the pharmaceutical market as a dedicated provider of addiction treatment therapies.

Website

Location

10710 Midlothian Turnpike

North Chesterfield, VA, 23235

United States

Social

What share of all stock conversation is about INDV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging to create a diversified CNS biopharmaceutical leader with significant scale, with a combined annual revenue of $2.2 billion.
The merger will give Supernus shareholders 1.54 Indivior shares for every share they own, and Indivior will provide a $1 billion special cash dividend to its shareholders before the deal closes.
The combined company will have 11 approved drugs in its portfolio and is expected to generate $125 million in annual cost savings.

Generated by AI

Sentiment

Of the messages about INDV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	96.08% +10.18
Bearish	—	0%	0% 0	3.92% -10.18

Nov 3

Indivior PLC has reported Q3 results that beat expectations and raised full-year guidance, leading to a re-pricing of the stock higher on both the top-line beat and the forward.
The company's earnings and guidance have driven a significant increase in the stock price, with Indivior shares up 5.2% due to the positive news.
Indivior's Q3 results have been met with enthusiasm from buyers, with a microscopic float and a high volume of 1.08M, indicating a strong demand for the stock.

Generated by AI

Topics

Of the messages about INDV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	41.17%
Technical Analysis	—	—	0%	46.62%
Earnings	—	—	0%	1.3%
Analysts	—	—	0%	2.73%
Controversies	—	—	0%	5.45%
Macro	—	—	0%	2.73%

Aug 3

Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive tax-free, all-stock merger of equals agreement, with Supernus stockholders receiving 1.54 Indivior shares per share, representing a value of $61.62 per Supernus share.
The combined company will have a pro forma net revenue of $2.2B, pro forma adjusted EBITDA of $888M, and 11 commercial products across CNS biopharmaceuticals, with a $1B special cash dividend before the deal closes.
Indivior reported Q2 2026 total net revenue of $343M, a 14% year-over-year increase, with SUBLOCADE revenue reaching a record $253M, and the company raising its FY26 guidance for revenue to $1.295B-$1.365B.

Generated by AI

Community

Of the messages about INDV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	6.45%	45.71%
Newcomers	—	100%	93.55%	54.29%

Aug 3

The merger between Supernus Pharmaceuticals and Indivior Pharmaceuticals is expected to close in Q4 2026, with Supernus shareholders receiving 1.54 Indivior shares for every share they own, and Indivior shareholders receiving a $1 billion special cash dividend.
The combined company is expected to generate $125 million in annual cost synergies and have a combined revenue of $2.2 billion.
The merger is seen as a move to create a diversified CNS biopharmaceutical leader with greater growth flexibility, and the combined company's market capitalization is estimated to be around $4.9 billion.

Generated by AI

Indivior Pharmaceuticals

Social

Aug 3

Sentiment

Nov 3

Topics

Aug 3

Community

Aug 3

News

Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior

Indivior (INDV) Receives a Rating Update from a Top Analyst

Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger

Indivior declares $8.13 special dividend contingent on merger

Indivior Pharmaceuticals to end supply agreement with Reckitt Benckiser in January

Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?

Also Discussed

Indivior Pharmaceuticals, Inc.

Company Information

Location

News

Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior

Indivior (INDV) Receives a Rating Update from a Top Analyst

Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger

Indivior declares $8.13 special dividend contingent on merger

Indivior Pharmaceuticals to end supply agreement with Reckitt Benckiser in January

Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?

Also Discussed

Social

Aug 3

Sentiment

Nov 3

Topics

Aug 3

Community

Aug 3